Pfizer won U.S. approval for its drug tafamidis to treat a rare heart disease, but whether the treatment that costs $225,000 year will be covered by heath insurers and employers remains unclear
for its drug tafamidis to treat a rare heart disease, but whether the treatment that costs $225,000 year will be covered by heath insurers and employers remains unclear.
“This drug is currently excluded from our National Preferred Formulary until our Pharmacy and Therapeutics Committee reviews and provides guidance,” a spokeswoman for the PBM Express Scripts, a unit of health insurer Cigna said, referring to the board of doctors that reviews clinical research for medications and advises whether the medicine should be included on preferred lists of drugs known as a formularies. “We don’t have a timeframe on that at the moment.
No matter whether the drug is covered or not by health insurance companies, the industry says the cost of such drugs will eventually hit consumers directly and that comes as a result of drug maker pricing decisions.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain ManagementPfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined the MediLedger Project Contracting and Chargebacks working group that is using blockchain technology to dramatically improve the complex process of chargebacks.
Weiterlesen »
Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain ManagementPfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined the MediLedger Project Contracting and Chargebacks working group that is using blockchain technology to dramatically improve the complex process of chargebacks.
Weiterlesen »
Pfizer gets U.S. approval for $225,000 a year heart drugThe U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral ...
Weiterlesen »
Pfizer posts earnings beat, raises 2019 profit forecastPfizer Inc on Tuesday beat Wall Street estimates for quarterly profit and slight...
Weiterlesen »
Three major pharmaceutical companies just reported earnings — here's how they didShares of pharmaceutical giants Pfizer and Merck rose in premarket trading after reporting first-quarter financial results that beat Wall Street's expectations.
Weiterlesen »
Pfizer gets U.S. approval for $225,000 a year heart drugThe U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral ...
Weiterlesen »
Patients are paying up to 20 times more for neurological drugs since 2004, study findsOut-of-pocket costs for Americans with neurologic conditions have risen so rapidly over 12 years, a new study says, that doctors need better access to drug price information 'to minimize patient financial burden.'
Weiterlesen »
Tom Brady says it's OK he's not the NFL's highest-paid quarterback—here's whyNew England Patriots star quarterback Tom Brady is known as one of the best players in NFL history. But, despite his long list of accomplishments, he is still not the highest-paid player, or even highest-paid quarterback, in the league.
Weiterlesen »
Pfizer posts earnings beat, raises 2019 profit forecastPfizer Inc on Tuesday beat Wall Street estimates for quarterly profit and slight...
Weiterlesen »
Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain ManagementPfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined the MediLedger Project Contracting and Chargebacks working group that is using blockchain technology to dramatically improve the complex process of chargebacks.
Weiterlesen »
Pfizer And Others Join Working Group To Use Blockchain Protocol For Supply Chain ManagementPfizer Inc., McKesson Corporation, AmerisourceBergen Corporation, and Premier Inc. have all joined the MediLedger Project Contracting and Chargebacks working group that is using blockchain technology to dramatically improve the complex process of chargebacks.
Weiterlesen »